Sava Infond d.o.o. Has $388,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Sava Infond d.o.o. cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 740 shares of the biopharmaceutical company’s stock after selling 60 shares during the period. Sava Infond d.o.o.’s holdings in Regeneron Pharmaceuticals were worth $388,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quent Capital LLC boosted its position in Regeneron Pharmaceuticals by 9.8% in the second quarter. Quent Capital LLC now owns 438 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 39 shares in the last quarter. 111 Capital acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $517,000. Ameritas Advisory Services LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $45,000. Greenwood Capital Associates LLC lifted its position in shares of Regeneron Pharmaceuticals by 52.3% during the second quarter. Greenwood Capital Associates LLC now owns 12,861 shares of the biopharmaceutical company’s stock worth $6,752,000 after purchasing an additional 4,419 shares in the last quarter. Finally, Ashton Thomas Securities LLC lifted its position in shares of Regeneron Pharmaceuticals by 6.1% during the second quarter. Ashton Thomas Securities LLC now owns 1,192 shares of the biopharmaceutical company’s stock worth $626,000 after purchasing an additional 69 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $600.00 on Friday. The stock has a market cap of $63.59 billion, a P/E ratio of 15.12, a P/E/G ratio of 1.92 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The company has a fifty day moving average price of $572.12 and a two-hundred day moving average price of $567.94. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,024.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter last year, the company posted $11.56 earnings per share. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on REGN shares. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research report on Monday, August 4th. Jefferies Financial Group upped their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. UBS Group reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Citigroup reiterated a “buy” rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Saturday, September 27th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.